Skip to content

Xabo FY010A

by Christoph Miethke GmbH & Co. KG

Xabo FY010A is a peritoneal/atrial cerebrospinal fluid catheter (FDA Class II; FDA product code JXG, Shunt, central nervous system and components) made by Christoph Miethke GmbH & Co. KG, listed in FDA GUDID since 31 May 2025 (UDI-DI 04041906506674), registry data as of 23 Oct 2026.

Listed FDA GUDID listing, no authorization on record

Valid until

Not applicable

Database listing, no authorization

FDA recalls

Not checked

No FDA submission to match recalls against

Documents

None

No authorization documents

Trust

Unverified

Source GUDID, synced 23 Oct 2026.

Regulatory status

as of registry sync 23 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesGUDID listing Number04041906506674 UDI-DI Date31 May 2025ListedStatusListed GUDID: in commercial distribution

Official records

From the FDA record

Device description
XABO PERITONEAL CATHETER 600MM
MRI safety
MR Safe
Natural rubber latex
Labelled as not made with natural rubber latex
Sterility
Supplied sterile

From the GUDID record (AccessGUDID), as read on 23 Oct 2026, as the labeller entered it.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — GUDID listing Listed

Specification

GUDID

Trade name
Xabo
Generic name
Peritoneal/atrial cerebrospinal fluid catheter
Model / Ref / Catalog
FY010A
Primary DI / UDI-DI
04041906506674
FDA product code
JXG
GMDN term
Peritoneal/atrial cerebrospinal fluid catheter
Device class
Class II
Regulation number
882.5550
GUDID distribution status
In Commercial Distribution
MRI safety
MR Safe

Similar devices in this category

Other devices filed under Peritoneal/atrial cerebrospinal fluid catheter.

Other devices from Christoph Miethke GmbH & Co. KG

See all devices from Christoph Miethke GmbH & Co. KG →

Properties

  • Supplied sterile
  • Single use
  • Implantable
  • Prescription use
  • Combination product
  • Lot / batch number
  • Expiration date
Other properties (8, all answered No)